Skip to content

Study · In vitro (cells) · 1997

8 results

IGF-binding protein-6 is involved in growth inhibition in SH-SY5Y human neuroblastoma cells: its production is both IGF- and cell density-dependent.

Babajko S, Leneuve P, Loret C, Binoux M

The Journal of endocrinology1 Feb 1997Cited by 25 (Europe PMC)

PMID9071979 (opens in a new tab)DOI10.1677/joe.0.1520221 (opens in a new tab)PepBankPUB-09071979
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In SH-SY5Y cells, des(1‑3)IGF-I had greater mitogenic potency than IGF-I after 24 h.

    In plain wordsIn cells, des(1‑3)IGF-I stimulated growth more strongly than IGF-I after 24 h.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseMitogenic potency at 24 hours versus IGF-I
    Study

    n: not reported in source

    SH-SY5Y human neuroblastoma cells
    Comparator
    IGF-I
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 24 hAs given in this study.

    Source sentences

    Summary
    After 24 h of culture, comparative mitogenic potencies were: des(1-3)IGF-I > IGF-I > IGF-II > insulin.
    1 context sentence
    Summary · context
    We have examined the expression and functions of IGFBPs produced by the neuroblastoma cell line, SH-SY5Y, in the presence of: insulin, IGF-I, IGF-II, des(1-3)IGF-I (an IGF-I analogue with weak affinity for IGFBPs), acidic fibroblast growth factor, basic fibroblast growth factor, or nerve growth factor.
  2. 02LabIn vitro (cells)Activity measurement

    In SH-SY5Y cells, des(1‑3)IGF-I had greater mitogenic potency than IGF-II after 24 h.

    In plain wordsIn cells, des(1‑3)IGF-I stimulated growth more strongly than IGF-II after 24 h.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseMitogenic potency at 24 hours versus IGF-II
    Study

    n: not reported in source

    SH-SY5Y human neuroblastoma cells
    Comparator
    IGF-II
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 24 hAs given in this study.

    Source sentences

    Summary
    After 24 h of culture, comparative mitogenic potencies were: des(1-3)IGF-I > IGF-I > IGF-II > insulin.
    1 context sentence
    Summary · context
    We have examined the expression and functions of IGFBPs produced by the neuroblastoma cell line, SH-SY5Y, in the presence of: insulin, IGF-I, IGF-II, des(1-3)IGF-I (an IGF-I analogue with weak affinity for IGFBPs), acidic fibroblast growth factor, basic fibroblast growth factor, or nerve growth factor.
  3. 03LabIn vitro (cells)Activity measurement

    In SH-SY5Y cells, des(1‑3)IGF-I had greater mitogenic potency than insulin after 24 h.

    In plain wordsIn cells, des(1‑3)IGF-I stimulated growth more strongly than insulin after 24 h.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseMitogenic potency at 24 hours versus insulin
    Study

    n: not reported in source

    SH-SY5Y human neuroblastoma cells
    Comparator
    Insulin
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 24 hAs given in this study.

    Source sentences

    Summary
    After 24 h of culture, comparative mitogenic potencies were: des(1-3)IGF-I > IGF-I > IGF-II > insulin.
    1 context sentence
    Summary · context
    We have examined the expression and functions of IGFBPs produced by the neuroblastoma cell line, SH-SY5Y, in the presence of: insulin, IGF-I, IGF-II, des(1-3)IGF-I (an IGF-I analogue with weak affinity for IGFBPs), acidic fibroblast growth factor, basic fibroblast growth factor, or nerve growth factor.
  4. 04LabIn vitro (cells)Activity measurement

    In SH-SY5Y cells, des(1‑3)IGF-I remained more mitogenically active than IGF-I after 48 h.

    In plain wordsIn cells, des(1‑3)IGF-I remained more active in stimulating growth than IGF-I after 48 h.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseMitogenic potency at 48 hours versus IGF-I
    Study

    n: not reported in source

    SH-SY5Y human neuroblastoma cells
    Comparator
    IGF-I
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 48 hAs given in this study.

    Source sentences

    Summary
    After 48 h, when IGFBP-2 and IGFBP-4 concentrations in the culture media had increased, des(1-3)IGF-I remained the most active, but the activity of insulin now equalled or exceeded that of IGF-I and IGF-II.
    1 context sentence
    Summary · context
    We have examined the expression and functions of IGFBPs produced by the neuroblastoma cell line, SH-SY5Y, in the presence of: insulin, IGF-I, IGF-II, des(1-3)IGF-I (an IGF-I analogue with weak affinity for IGFBPs), acidic fibroblast growth factor, basic fibroblast growth factor, or nerve growth factor.
  5. 05LabIn vitro (cells)Activity measurement

    In SH-SY5Y cells, des(1‑3)IGF-I remained more mitogenically active than IGF-II after 48 h.

    In plain wordsIn cells, des(1‑3)IGF-I remained more active in stimulating growth than IGF-II after 48 h.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseMitogenic potency at 48 hours versus IGF-II
    Study

    n: not reported in source

    SH-SY5Y human neuroblastoma cells
    Comparator
    IGF-II
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 48 hAs given in this study.

    Source sentences

    Summary
    After 48 h, when IGFBP-2 and IGFBP-4 concentrations in the culture media had increased, des(1-3)IGF-I remained the most active, but the activity of insulin now equalled or exceeded that of IGF-I and IGF-II.
    1 context sentence
    Summary · context
    We have examined the expression and functions of IGFBPs produced by the neuroblastoma cell line, SH-SY5Y, in the presence of: insulin, IGF-I, IGF-II, des(1-3)IGF-I (an IGF-I analogue with weak affinity for IGFBPs), acidic fibroblast growth factor, basic fibroblast growth factor, or nerve growth factor.
  6. 06LabIn vitro (cells)Activity measurement

    In SH-SY5Y cells, des(1‑3)IGF-I remained more mitogenically active than insulin after 48 h.

    In plain wordsIn cells, des(1‑3)IGF-I remained more active in stimulating growth than insulin after 48 h.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseMitogenic potency at 48 hours versus insulin
    Study

    n: not reported in source

    SH-SY5Y human neuroblastoma cells
    Comparator
    Insulin
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 48 hAs given in this study.

    Source sentences

    Summary
    After 48 h, when IGFBP-2 and IGFBP-4 concentrations in the culture media had increased, des(1-3)IGF-I remained the most active, but the activity of insulin now equalled or exceeded that of IGF-I and IGF-II.
    1 context sentence
    Summary · context
    We have examined the expression and functions of IGFBPs produced by the neuroblastoma cell line, SH-SY5Y, in the presence of: insulin, IGF-I, IGF-II, des(1-3)IGF-I (an IGF-I analogue with weak affinity for IGFBPs), acidic fibroblast growth factor, basic fibroblast growth factor, or nerve growth factor.
  7. 07LabIn vitro (cells)Activity measurement

    In high-density SH-SY5Y cultures, mitogenic activity diminished with high des(1‑3)IGF-I concentrations as IGFBP-6 appeared.

    In plain wordsIn cells at high density, growth activity diminished with high des(1‑3)IGF-I concentrations as IGFBP-6 appeared.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseMitogenic activity at high density and concentration
    Study

    n: not reported in source

    SH-SY5Y human neuroblastoma cells
    Outcome group
    Tumor growth · Cancer
    Studied dose
    40 ng/mlAs given in this study.

    Measurements

    Des IGF-I concentration
    40 ng/ml
    high cell density

    Source sentences

    Summary
    At high cell density and with high concentrations of IGF-I, des(1-3)IGF-I (40 ng/ml) or IGF-II (80 ng/ml), the mitogenic activities of the IGFs diminished concomitantly with the appearance in the culture medium of an additional IGFBP identified as IGFBP-6, whose production depended on activation of…
    1 context sentence
    Summary · context
    We have examined the expression and functions of IGFBPs produced by the neuroblastoma cell line, SH-SY5Y, in the presence of: insulin, IGF-I, IGF-II, des(1-3)IGF-I (an IGF-I analogue with weak affinity for IGFBPs), acidic fibroblast growth factor, basic fibroblast growth factor, or nerve growth factor.
  8. 08LabIn vitro (cells)Mechanism

    In high-density SH-SY5Y cultures, IGFBP-6 appeared with high des(1‑3)IGF-I concentrations and depended on type 1 IGF receptor activation.

    In plain wordsIn cells at high density, IGFBP-6 appeared with high des(1‑3)IGF-I concentrations and depended on IGF receptor activation.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    IncreaseIGFBP-6 appearance
    Study

    n: not reported in source

    SH-SY5Y human neuroblastoma cells
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    40 ng/mlAs given in this study.

    Source sentences

    Summary
    At high cell density and with high concentrations of IGF-I, des(1-3)IGF-I (40 ng/ml) or IGF-II (80 ng/ml), the mitogenic activities of the IGFs diminished concomitantly with the appearance in the culture medium of an additional IGFBP identified as IGFBP-6, whose production depended on activation of…
    1 context sentence
    Summary · context
    We have examined the expression and functions of IGFBPs produced by the neuroblastoma cell line, SH-SY5Y, in the presence of: insulin, IGF-I, IGF-II, des(1-3)IGF-I (an IGF-I analogue with weak affinity for IGFBPs), acidic fibroblast growth factor, basic fibroblast growth factor, or nerve growth factor.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.